Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial (Q102060102)
Jump to navigation
Jump to search
scientific article published on 01 November 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial |
scientific article published on 01 November 2020 |
Statements
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial (English)
Artur Jurczyszyn
Sebastian Grosicki
Holger W Auner
1 reference
Maryana Simonova
Ivan Spicka
Ludek Pour
Iryrna Kriachok
Maria Gavriatopoulou
Halyna Pylypenko
Xavier Leleu
Vadim Doronin
Ganna Usenko
Nizar J Bahlis
Roman Hajek
Reuben Benjamin
Tuphan K Dolai
Dinesh K Sinha
Christopher P Venner
Mamta Garg
Mercedes Gironella
Pawel Robak
Monica Galli
Craig Wallington-Beddoe
Atanas Radinoff
Galina Salogub
Don A Stevens
Supratik Basu
Anna M Liberati
Hang Quach
Vesselina S Goranova-Marinova
Jelena Bila
Eirini Katodritou
Hanna Oliynyk
Sybiryna Korenkova
Jeevan Kumar
Sundar Jagannath
Phillipe Moreau
Moshe Levy
Darrell White
Moshe E Gatt
Thierry Facon
Maria V Mateos
Michele Cavo
Donna Reece
Larry D Anderson
Jean-Richard Saint-Martin
Jacqueline Jeha
Anita A Joshi
Yi Chai
Lingling Li
Vishnuvardhan Peddagali
Melina Arazy
Jatin Shah
Sharon Shacham
Michael G Kauffman
Meletios A Dimopoulos
Paul G Richardson
1 November 2020